PerkinElmer finalizes Caliper Life Sciences acquisition

PerkinElmer (NYSE: PKI; Waltham, MA) has finalized its acquisition of imaging and detection solutions provider Caliper Life Sciences (NASDAQ: CALP; Hopkinton, MA). In September, PerkinElmer announced its intent to acquire Caliper for $10.50 per share, for a total net purchase price of approximately $600 million in cash.

The acquisition looks to strengthen PerkinElmer's position in personalized medicine, says Robert F. Friel, PerkinElmer chairman and CEO, and provide expanded offerings across the company's biomedical, diagnostics, environmental, and food safety end-markets.

Also, PerkinElmer has named Kevin Hrusovsky, who was Caliper’s CEO, as the head of a newly combined $500 million business that integrates the former Caliper organization with PerkinElmer’s existing research business.